Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 0.95 |
| ▸ | USP2 | O75604 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 2/20 | 0.95 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 5/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betazole SCHEMBL1237745 | 1.00 | — | — | |
| Betazole SCHEMBL3336050 | 0.98 | HRH2 (1.00) | HRH2USP2LMNAHRH4HRH3 | |
| Betazole SCHEMBL157156 | 0.98 | — | — | |
| Betazole SCHEMBL1649674 | 0.95 | HRH2 (0.95) | HRH2USP2LMNAHRH4HRH3 | |
| SCHEMBL4711257 | 0.84 | — | — | |
| Betazole SCHEMBL3336046 | 0.80 | USP2 (0.68) | HRH2USP2LMNAHRH4HRH3 | |
| SCHEMBL2183872 | 0.78 | — | — | |
| SCHEMBL21721708 | 0.74 | — | — | |
| SCHEMBL4222977 | 0.74 | — | — | |
| Bromide SCHEMBL10400923 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117996825-A | Optimal control method for cogeneration based on hydrogen fuel cell technology | 国网山东省电力公司电力科学研究院 | 2024-05-07 | — | — | CN | claimed |
| EP-4251163-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-4251167-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-4251165-A1 | MORPHOLINO DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-4251152-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-4251156-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| WO-2022115546-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| WO-2022115545-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| WO-2022115558-A1 | MORPHOLINO DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| WO-2022115549-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| WO-2022115543-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| WO-2026043901-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING ENTEROVIRUSES WITH VAPENDAVIR SULFATE | Altesa BioSciences, Inc. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20260048050-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING ENTEROVIRUSES WITH VAPENDAVIR SULFATE | Altesa BioSciences, Inc. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LC (US) | 2025-10-28 | — | — | US | disclosed |
| US-12414955-B2 | Anti-viral activity of VPS34 inhibitors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2022115543-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115546-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115558-A1 | MORPHOLINO DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115545-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115549-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414955-B2 | Anti-viral activity of VPS34 inhibitors | SARS1, VPS26B, VPS4B | HRH2 4366/4885USP2 249/4885LMNA 3975/4885 |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | HRH2 3545/4885USP2 796/4885LMNA 2391/4885 |
| US-20260048050-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING ENTEROVIRUSES WITH VAPENDAVIR SULFATE | RPP30, EXOSC9, RPL30 | HRH2 1570/4885USP2 4260/4885LMNA 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.